Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

Inclusion Criteria * Signed Informed Consent Form, prior to screening evaluations * In good physical and mental health * Pre-menopausal females between the ages of 18-35 years (both inclusive) at the time of randomisation * Regular menstrual cycles of 26-35 days duration (both inclusive), presumed to be ovulatory * Body mass index (BMI) between 18 and 29 kg/m2 (both inclusive) * Willing to donate the retrieved oocytes * Willing to use an adequate barrier method of contraception from informed consent to Day hCG injection +7 and to use an adequate barrier or hormonal method of contraception from Day hCG injection +7 to the end-of-study visit Exclusion Criteria * Abnormal karyotype * Any known clinically significant systemic disease (e.g., insulin dependent diabetes) * Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the study * Diagnosed with polycystic ovarian syndrome or endometriosis stage III/IV * Diagnosed as "poor responder" * History of recurrent miscarriage (defined as three consecutive spontaneous losses before weeks 24 of pregnancy) * Pregnancy or lactation * Use of any investigational drug during 3 months prior to start of the current COH cycle * Previous participation in the study * Hypersensitivity to any trial product